← All trials
NCT05781542
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2025
- First posted
- Mar 23, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 46
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Access to Advanced Health Institute (AAHI)Collaborator
- Department of Health and Human ServicesCollaborator
- HIV Vaccine Trials NetworkCollaborator
- Inovio PharmaceuticalsCollaborator
- The Wistar InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.